Growth deficits in children treated with desipramine: a controlled study
- PMID: 1564024
- DOI: 10.1097/00004583-199203000-00009
Growth deficits in children treated with desipramine: a controlled study
Abstract
Using multiple assessment methods, growth deficits in weight and height were examined in a clinical sample of children and adolescents with attention deficit hyperactivity disorder treated chronically (mean 14 months) with desipramine (DMI) and two comparison samples of children treated chronically with methylphenidate (MPH) and a not-treated group. Although there were statistically significant weight deficits in children treated with both DMI and MPH compared with normal controls, only those treated with MPH sustained height deficits that attained statistical significance. It appears that DMI may be an appropriate alternative for patients with stimulant-associated severe suppression of growth in height.
Comment in
-
Growth deficits and desipramine.J Am Acad Child Adolesc Psychiatry. 1992 Nov;31(6):1167-8. doi: 10.1097/00004583-199211000-00031. J Am Acad Child Adolesc Psychiatry. 1992. PMID: 1429424 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical